World EPA Congress Europe

March 12-13, 2024 | Amsterdam, the Netherlands

We are excited to announce that we will be attending and speaking at World EPA Congress, Europe’s largest congress in market access, pricing, and evidence featuring 300 speakers, multiple streams, and over 1,000 attendees from pharma and biotech.

Make sure you join us for our presentation “Maximizing Launches for Rare Disease Treatments: Strategies and Insights” and connect with our delegates on-site!

Events
Published on:
February 20, 2024

Join Our Presentation!

Maximizing Launches for Rare Disease Treatments:
Strategies and Insights

March 13 | 12:05 CET

In the complex landscape of rare disease treatment development, the journey from discovery to delivery is fraught with unique challenges. These include the intricacies of understanding rare conditions, navigating regulatory pathways, ensuring patient access, and establishing fair pricing models. At the World Evidence, Pricing, and Access Congress, we will explore innovative strategies to overcome these hurdles and maximize the impact of rare disease treatment launches.

Our discussion will delve into the importance of robust evidence generation, leveraging real-world evidence alongside traditional clinical trials to build a compelling value proposition. We will examine how early and continuous engagement with regulatory agencies, patients, and payers can streamline the approval process and ensure treatments meet the real needs of those affected by rare diseases.

The presentation will highlight case studies of successful rare disease treatment launches, focusing on key factors such as targeted patient identification, innovative pricing and reimbursement models, and the role of patient advocacy groups in facilitating access. Additionally, we will explore the potential of digital health technologies in enhancing patient outcomes and supporting evidence collection post-launch.

About Our Speakers

Ahmad Bechara

Ahmad Bechara

EVP, Pharma Ahmad Bechara is serving as EVP Pharma at Alira Health. With over 20 years of experience in consulting services, the pharmaceutical industry and academic research, Ahmad is a seasoned professional in healthcare innovation, recognized for his strategic leadership and unwavering commitment to industry transformation.

In his prior roles, Ahmad led the Global Market Access Practice at Alira Health, where he spearheaded numerous global pricing and market access initiatives and demonstrated his expertise in developing actionable strategies across diverse therapeutic areas, including auto-immune and inflammatory diseases, cardiometabology, haematology, oncology, and rare diseases. His contribution to the successful launch of more than 15 blockbusters underscores his ability in navigating complex market dynamics.

Prior to his tenure at Alira Health, Ahmad dedicated over 7 years to various roles at Novartis, including within the Global Market Access Team.
Ahmad holds a PhD in Genetics and Neuroscience from the University of Claude Bernard, Lyon, France where he researched the molecular mechanisms of topographic brain map formation and plasticity. He has authored and co-authored multiple publications in the market access/pricing, genetic and neuroscience fields.
Andrea Mantovani

Andrea Mantovani

Partner Consulting, Value, Access and Pricing Andrea has more than 27 years of consulting and pharmaceutical industry experience. His expertise is in strategy, marketing and sales, public affairs, pricing, and market access, with a track record of over 30 transactions.

Prior to joining Alira Health, Andrea worked at Andersen Consulting (now Accenture) and held senior management roles for big pharma companies in the UK, Spain, and Italy, including Sanofi, Amgen, Abbott, and Novartis, where he spent five years at the regional headquarters, overseeing activities in 28 countries and spearheading transformational value and access projects.​

Andrea holds a degree in marketing and economics from the University of Verona, and an MBA from SDA Bocconi Business School, including courses in healthcare and pharmaceuticals. He is a contract professor for market access and public affairs at LUISS Business School and an external lecturer for the MAMIL Master, a joint program by H-Farm and Humanitas University.
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.